Visual Abstract

graphic
View largeDownload slide
Keywords:
Kidney transplant, Oxalate, Graft function, Roux-en-Y gastric bypass surgery

Introduction: This study describes patient characteristics and examines graft function of kidney transplant recipients (without primary hyperoxaluria) with elevated plasma oxalate (POx) and enteric risk factors prior to transplant at our institution. Methods: Kidney transplant recipients between 2012 and 2020 with elevated POx at the time of kidney transplant evaluation were included. A matched control cohort was gathered using patient/donor age, living/deceased donor type, panel reactive antibody, kidney donor profile index, and human leukocyte antigen mismatch as matching variables. Graft function at 1 year and at last follow-up was reported. Results: A total of 106 patients with elevated POx were identified. A third of the patients had Roux-en-Y gastric bypass, a third had other enteric risks, and a third did not have an identifiable enteric risk. Median eGFR (estimated glomerular filtration rate) at 1 year and at last follow-up was similar between cases and controls except for subgroup of patients with pre-transplant POx >30 µmol/L where 1-year eGFR was lower compared to controls. Across eGFR categories, more cases were in eGFR category <30 mL/min/1.73 m2 compared to controls. Conclusion: Roux-en-Y gastric bypass is the most common identifiable risk for elevated POx in kidney transplant candidates. 1-year graft function was not inferior in cases compared to matched controls except for subgroup with POx >30 µmol/L pre-transplant.

Keywords:
Kidney transplant, Oxalate, Graft function, Roux-en-Y gastric bypass surgery
1.
Mitchell T, Kumar P, Reddy T, Wood KD, Knight J, Assimos DG, et al. Dietary oxalate and kidney stone formation. Am J Physiol Renal Physiol. 2019 Mar 1;316(3):F409–13.
2.
Hagler L, Herman RH. Oxalate metabolism. I. Am J Clin Nutr. 1973 Jul;26(7):758–65.
3.
Latta K, Brodehl J. Primary hyperoxaluria type I. Eur J Pediatr. 1990 May;149(8):518–22.
4.
Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, et al. Kidney stones. Nat Rev Dis Primers. 2016 Feb 25;2(1):16008.
5.
Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ, et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 2013 Nov;84(5):895–901.
6.
Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest. 2013 Jan;123(1):236–46.
7.
Mulay SR, Eberhard JN, Desai J, Marschner JA, Kumar SVR, Weidenbusch M, et al. Hyperoxaluria requires TNF receptors to initiate crystal adhesion and kidney stone disease. J Am Soc Nephrol. 2017 Mar;28(3):761–8.
8.
Cuvelier C, Goffin E, Cosyns JP, Wauthier M, de Strihou Cv Y. Enteric hyperoxaluria: a hidden cause of early renal graft failure in two successive transplants: spontaneous late graft recovery. Am J Kidney Dis. 2002 Jul;40(1):E3.
9.
Karaolanis G, Lionaki S, Moris D, Palla VV, Vernadakis S. Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts. Transpl Rev. 2014 Oct;28(4):182–7.
10.
Lumlertgul N, Siribamrungwong M, Jaber BL, Susantitaphong P. Secondary oxalate nephropathy: a systematic review. Kidney Int Rep. 2018 Nov;3(6):1363–72.
11.
Reddy S, Bolen E, Abdelmalek M, Lieske JC, Ryan M, Keddis MT. Clinical outcomes and histological patterns in oxalate nephropathy due to enteric and nonenteric risk factors. Am J Nephrol. 2021;52(12):961–8.
12.
Hoppe B, Kemper MJ, Bokenkamp A, Portale AA, Cohn RA, Langman CB. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 1999 Jul;56(1):268–74.
13.
Nelson WK, Houghton SG, Milliner DS, Lieske JC, Sarr MG. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005 Sep-Oct;1(5):481–5.
14.
Roodnat JI, de Mik-van Egmond AME, Visser WJ, Berger SP, van der Meijden WAG, Knauf F, et al. A successful approach to kidney transplantation in patients with enteric (secondary) hyperoxaluria. Transpl Direct. 2017 Dec;3(12):e331.
15.
Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case ratio in matched case-control studies. Am J Epidemiol. 1999 Jan 15;149(2):195–7.
16.
Thomas IA, Gaynor JJ, Joseph T, De La Cruz-Munoz N, Sageshima J, Kupin W, et al. Roux-en-Y gastric bypass is an effective bridge to kidney transplantation: results from a single center. Clin Transpl. 2018 May;32(5):e13232.
17.
Soliman BG, Tariq N, Law YY, Yi S, Nwana N, Bosetti R, et al. Effectiveness of bariatric surgery in increasing kidney transplant eligibility in patients with kidney failure requiring dialysis. Obes Surg. 2021 Aug;31(8):3436–43.
18.
Nasr SH, D’Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, et al. Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol. 2008 Nov;3(6):1676–83.
19.
Troxell ML, Houghton DC, Hawkey M, Batiuk TD, Bennett WM. Enteric oxalate nephropathy in the renal allograft: an underrecognized complication of bariatric surgery. Am J Transpl. 2013 Feb;13(2):501–9.
20.
Taheri D, Sarmadi T, Shahidi S, Taheri S, Mortazavi M, Atapour A, et al. Oxalate nephropathy after Jejuno-Ileal bypass surgery. Saudi J Kidney Dis Transpl. 2015 Sep;26(5):1026–7.
21.
Nazzal L, Puri S, Goldfarb DS. Enteric hyperoxaluria: an important cause of end-stage kidney disease. Nephrol Dial Transpl. 2016 Mar;31(3):375–82.
22.
Oniscu GC, Abramowicz D, Bolignano D, Gandolfini I, Hellemans R, Maggiore U, et al. Management of obesity in kidney transplant candidates and recipients: a clinical practice guideline by the DESCARTES Working Group of ERA. Nephrol Dial Transpl. 2021 Dec 24;37(Suppl 1):i1–15.
23.
Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M. Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis. 2022 May;79(5):717–27.
24.
Rankin AC, Walsh SB, Summers SA, Owen MP, Mansell MA. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transpl. 2008 Aug;8(8):1755–8.
25.
Waikar SS, Srivastava A, Palsson R, Shafi T, Hsu CY, Sharma K, et al. Association of urinary oxalate excretion with the risk of chronic kidney disease progression. JAMA Intern Med. 2019 Apr 1;179(4):542–51.
26.
Elgstoen KBP, Johnsen LF, Woldseth B, Morkrid L, Hartmann A. Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria. Nephrol Dial Transpl. 2010 Jul;25(7):2341–5.
27.
Tubben A, Sotomayor CG, Post A, Minovic I, Frelink T, de Borst MH, et al. Urinary oxalate excretion and long-term outcomes in kidney transplant recipients. J Clin Med. 2019 Dec 2;8(12):2104.
28.
Krogstad V, Elgstoen KBP, Johnsen LF, Hartmann A, Morkrid L, Asberg A. High plasma oxalate levels early after kidney transplantation are associated with impaired long-term outcomes. Transpl Int. 2022;35:10240.
29.
Pinheiro HS, Câmara NOS, Osaki KS, De Moura LAR, Pacheco-Silva A. Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival. Am J Transpl. 2005 Feb;5(2):323–9.
30.
Bagnasco SM, Mohammed BS, Mani H, Gandolfo MT, Haas M, Racusen LC, et al. Oxalate deposits in biopsies from native and transplanted kidneys, and impact on graft function. Nephrol Dial Transpl. 2009 Apr;24(4):1319–25.
31.
Perinpam M, Enders FT, Mara KC, Vaughan LE, Mehta RA, Voskoboev N, et al. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin Biochem. 2017 Dec;50(18):1014–9.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.